InsidersTradesSigma
Follow the UNITED THERAPEUTICS CORPORATION share price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). The latest transaction was reported on 10 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: JAN MALCOLM. The full history is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
3 of 3 declarations
UNITED THERAPEUTICS CORPORATION is a biopharmaceutical company focused on developing treatments for rare diseases, particularly pulmonary arterial hypertension. It emphasizes innovation and improving patient care.